Drugs Made In America Acquisition II Corp. $DMII Shares Newly Purchased by Wealthspring Capital LLC

Wealthspring Capital LLC purchased a new position in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 399,150 shares of the company’s stock, valued at approximately $4,063,000.

A number of other large investors have also recently made changes to their positions in the stock. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Drugs Made In America Acquisition II during the first quarter valued at approximately $19,960,000. Sona Asset Management US LLC lifted its position in Drugs Made In America Acquisition II by 66.7% during the first quarter. Sona Asset Management US LLC now owns 500,000 shares of the company’s stock valued at $4,985,000 after purchasing an additional 200,000 shares during the period. Kryger Capital LLC purchased a new stake in Drugs Made In America Acquisition II in the first quarter worth approximately $3,088,000. Rivernorth Capital Management LLC purchased a new stake in Drugs Made In America Acquisition II in the first quarter worth approximately $2,991,000. Finally, SkyView Investment Advisors LLC bought a new stake in Drugs Made In America Acquisition II in the 2nd quarter worth approximately $2,515,000.

Drugs Made In America Acquisition II Price Performance

Shares of NASDAQ:DMII opened at $10.21 on Monday. The stock’s 50-day simple moving average is $10.18 and its two-hundred day simple moving average is $10.08. Drugs Made In America Acquisition II Corp. has a 52-week low of $9.86 and a 52-week high of $10.33.

Drugs Made In America Acquisition II (NASDAQ:DMII) last released its quarterly earnings results on Friday, August 14th. The company reported $0.07 EPS for the quarter.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on DMII shares. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st. Wall Street Zen raised Drugs Made In America Acquisition II to a “hold” rating in a report on Saturday, October 24th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II is a special purpose acquisition company, or SPAC. It was formed to pursue a merger, acquisition or similar business combination with an operating company.

The company has identified the pharmaceutical sector as its area of focus, with an emphasis on businesses connected to the production of drugs in the United States. It does not operate a drug-manufacturing or pharmaceutical business of its own.